In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on ChemoCentryx (NASDAQ: CCXI), with a price target of $20. The company’s shares closed yesterday at $11.52.
According to TipRanks.com, White is a 5-star analyst with an average return of 23.3% and a 51.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ChemoCentryx with a $16.70 average price target.
See today’s analyst top recommended stocks >>
ChemoCentryx’s market cap is currently $579.6M and has a P/E ratio of 33.88. The company has a Price to Book ratio of 20.04.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.
